| 生物活性 | |||
|---|---|---|---|
| 描述 | Ralaniten triacetate (EPI-506), a precursor of Ralaniten, is the first orally active inhibitor targeting the androgen receptor (AR) N-terminal domain (NTD). It is effective against both the full-length AR and variants associated with resistance, such as AR-v7[1][2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.92mL 0.38mL 0.19mL |
9.60mL 1.92mL 0.96mL |
19.19mL 3.84mL 1.92mL |
| 参考文献 |
|---|